0KSX.LSE Quest Diagnostics Inc.
- Market cap
- -
- P/E
- 16.6x
- P/B
- -
- ROE
- 15.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 0KSX.LSE undervalued?
Graham numberThe Graham number of Quest Diagnostics Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Quest Diagnostics Inc. fundamental analysis
No fundamental analysis for Quest Diagnostics Inc. yet.
Quest Diagnostics Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Quest Diagnostics Inc.
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consum…
Full company profileQuest Diagnostics Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Quest Diagnostics Inc. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 7.52B | 7.40B | 7.53B | 7.73B | 9.44B | 10.8B | 9.88B | 9.25B | 9.87B | 11.0B | 12.0B |
| Gross Profit | 2.87B | 2.66B | 2.58B | 2.63B | 3.61B | 4.14B | 3.35B | 2.96B | 3.15B | 3.52B | 3.92B |
| Operating Income | 1.23B | 1.28B | 1.22B | 1.22B | 2.11B | 2.44B | 1.62B | 1.33B | 1.42B | 1.60B | 1.81B |
| EBITDA | 1.48B | 1.45B | 1.40B | 1.59B | 2.41B | 3.16B | 1.82B | 1.73B | 1.89B | 2.17B | 2.20B |
| Net Income | 642M | 769M | 733M | 855M | 1.43B | 1.99B | 942M | 850M | 866M | 992M | 1.18B |
| EPS | 4.52 | 5.49 | 5.27 | 6.29 | 10 | 16 | 7.98 | 7.52 | 7.66 | 8.78 | 11 |
| Balance Sheet | |||||||||||
| Total Assets | 10.1B | 10.5B | 11.0B | 12.8B | 14.0B | 13.6B | 12.8B | 14.0B | 16.2B | 16.2B | 17.2B |
| Total Liabilities | 5.36B | 5.47B | 5.66B | 7.08B | 7.14B | 7.05B | 6.83B | 7.60B | 9.26B | 8.94B | 9.19B |
| Shareholders' Equity | 4.63B | 4.92B | 5.22B | 5.64B | 6.76B | 6.44B | 5.89B | 6.31B | 6.78B | 7.17B | 7.63B |
| Cash & Short-term Investments | 359M | 137M | 135M | 1.19B | 1.16B | 872M | 315M | 686M | 549M | 420M | 797M |
| Total Debt | 3.73B | 3.86B | 3.99B | 5.42B | 4.81B | 4.77B | 4.71B | 5.34B | 7.09B | 6.92B | 6.29B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.07B | 1.18B | 1.20B | 1.24B | 2.01B | 2.23B | 1.72B | 1.27B | 1.33B | 1.89B | 1.98B |
| Capital Expenditure | 293M | 252M | 383M | 400M | 418M | 403M | 404M | 408M | 425M | 527M | 557M |
| Free Cash Flow | 776M | 923M | 817M | 843M | 1.59B | 1.83B | 1.31B | 864M | 909M | 1.36B | 1.42B |
| Ratios | |||||||||||
| ROE | 13.9% | 15.6% | 14.1% | 15.2% | 21.1% | 30.9% | 16.0% | 13.5% | 12.8% | 13.8% | 15.4% |
| ROA | 6.4% | 7.3% | 6.7% | 6.7% | 10.2% | 14.6% | 7.3% | 6.1% | 5.4% | 6.1% | 6.8% |
| Net Profit Margin | 8.5% | 10.4% | 9.7% | 11.1% | 15.1% | 18.4% | 9.5% | 9.2% | 8.8% | 9.0% | 9.8% |
| Debt to Equity | 0.81x | 0.78x | 0.77x | 0.96x | 0.71x | 0.74x | 0.80x | 0.85x | 1.05x | 0.96x | 0.82x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Quest Diagnostics Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- 35.6%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | 353M | 3.12 | 35.6% |
| 2024 | USD 331M | 2.93 | 38.2% |
| 2023 | USD 314M | 2.78 | 36.9% |
| 2022 | USD 305M | 2.58 | 32.4% |
| 2021 | USD 309M | 2.41 | 15.5% |
| 2020 | USD 297M | 2.18 | 20.8% |
| 2019 | USD 286M | 2.10 | 33.5% |
| 2018 | USD 266M | 1.91 | 36.3% |
| 2017 | USD 247M | 1.76 | 32.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Quest Diagnostics Inc.
- Insiders 0.43%
- Institutions 98.72%
- Public & others 0.84%
- Free float 109M
Quest Diagnostics Inc. company profile
- Company name
- Quest Diagnostics Inc.
- Ticker
- 0KSX.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 60,000
- Fiscal year end
- December
- Address
- 500 Plaza Drive, Secaucus, NJ, United States, 07094
- Phone
- 973 520 2700
- Website
- questdiagnostics.com
About Quest Diagnostics Inc.
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Quest Diagnostics Inc. management
10- Mr. James E. DavisChairman, CEO & President · born 1963
- Mr. Sam A. SamadExecutive VP & CFO · born 1970
- Mr. Michael E. Prevoznik J.D.Senior VP & General Counsel · born 1962
- Ms. Catherine T. DohertyExecutive Vice President of Regional Businesses · born 1963
- Mr. Karthik Kuppusamy Ph.D.Senior Vice President of Clinical Solutions · born 1970
- Mr. Michael J. DeppeSenior VP, Corporate Controller & Chief Accounting Officer · born 1967
- Mr. Murali BalakumarSenior VP and Chief Information & Digital Officer
- Ms. Damini ChokshiVice President of Investor Relations
- Ms. Kristin Lee Wallace Esq.Senior VP & Chief Compliance Officer
- Mr. Garry ClarkSenior VP and Chief Marketing & Communications Officer